GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ADIL
Shares of Adial, a biopharmaceutical company developing a drug to treat alcoholism, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions.
Share prices of companies in the market segment - Narco farm
Adial Pharmaceuticals is a biopharmaceutical company developing a drug to treat alcohol use disorder in genetically predisposed patients. We've classified it as a "Drug Farm." The chart below shows how the market values the addiction treatment sector.
Broad Market Index - GURU.Markets
Adial Pharmaceuticals is a biopharmaceutical company developing treatments for addictions, particularly alcoholism. Its focus on this social issue makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Adial compares to it.
Change in the price of a company, segment, and market as a whole per day
ADIL - Daily change in the company's share price ADIL
Adial Pharmaceuticals, Inc.'s daily share price fluctuations reflect the high volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drug for treating alcohol addiction.
Daily change in the price of a set of shares in a market segment - Narco farm
Adial Pharmaceuticals develops medications for the treatment of addictions, including alcoholism. This is a socially significant but risky segment of the pharmaceutical industry. The chart below shows the average volatility in this niche. It will help you understand how ADIL's share price performance aligns with investor expectations in this sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Adial Pharmaceuticals develops medications for the treatment of alcohol use disorders. Given the severity of this social problem, its developments are attracting considerable attention. The company's shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ADIL
For Adial Pharmaceuticals, the year-to-date performance is a story about the development of its drug for the treatment of alcohol addiction. Its market capitalization over the next 12 months depends entirely on the results of clinical trials. The success of its genetically targeted approach could offer a new, personalized way to combat this serious disease.
Annual dynamics of market capitalization of the market segment - Narco farm
Adial, a late-stage biotech company developing drugs for the treatment of addictions, is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adial Pharmaceuticals is developing a drug for the treatment of alcohol addiction, targeting patients with a specific genetic profile. Its annual market capitalization dynamics, compared to the market, are a testament to personalized medicine. The company's success depends on the results of clinical trials and the ability to demonstrate the effectiveness of this approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ADIL
Adial Pharmaceuticals is developing a drug for the treatment of alcohol use disorders. Its monthly performance is entirely dependent on the results of its clinical trials. These trial data are binary events for its stock.
Monthly dynamics of market capitalization of the market segment - Narco farm
Adial Pharmaceuticals is developing a drug for the treatment of alcohol use disorders based on genetic testing. This is a personalized approach to addiction treatment. The company's success depends on the results of clinical trials. The pharmaceutical sector's schedule will reflect the overall interest in this complex yet socially significant area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adial Pharmaceuticals is developing a drug to treat alcohol addiction. This is a socially significant but risky area. The company's stock price is entirely dependent on the results of clinical trials and regulatory decisions. It has no correlation with overall market indices, as investors evaluate the research prospects solely.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol addiction in people with a specific genetic marker. Its weekly stock price has been a rollercoaster, driven by news of clinical trials. The success or failure of a single study determines the future of the entire company.
Weekly dynamics of market capitalization of the market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol addiction, targeting patients with a specific genotype. Its narrow focus makes its stock dependent on the success of a single product. The chart shows how the company's news affects its performance, independent of general pharmaceutical trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Adial Pharmaceuticals is developing a drug for alcoholism. The company's fate depends on the success of a single product. This chart shows how company news (such as trial data) affects its performance, completely separate from overall stock market trends.
Market capitalization of the company, segment and market as a whole
ADIL - Market capitalization of the company ADIL
Adial Pharmaceuticals' market capitalization chart reflects investor valuation of its alcohol addiction treatment drug. Its dynamics reflect the market's faith in its genetically targeted approach. Its high volatility and low price are a direct response to clinical trial results, which have been mixed so far but offer hope.
ADIL - Share of the company's market capitalization ADIL within the market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol addiction in people with a specific genetic profile. Its market share in the pharmaceutical sector is small, but it is focused on personalized medicine. Its capitalization is a bet on the success of its unique gene-targeting approach.
Market capitalization of the market segment - Narco farm
Below is a chart showing the total value of the entire legal cannabis and pharmaceutical sectors. For Adial, which is developing a drug to treat alcohol addiction, this line is a roadmap for the fight against addiction. Its dynamics show how much investors are willing to invest in new approaches to treating addiction, which is a huge social and medical problem.
Market capitalization of all companies included in a broad market index - GURU.Markets
Adial Pharmaceuticals is developing a drug to treat alcohol addiction. Its market capitalization reflects the potential of a solution to a huge social and medical problem. This represents the market share of the drug-based treatment of addiction.
Book value capitalization of the company, segment and market as a whole
ADIL - Book value capitalization of the company ADIL
Adial Pharmaceuticals develops drugs to treat addictions. Its book value represents its financial resources for R&D. It consists of cash, which allows the company to conduct clinical trials of its candidates. How has this vital capital changed? The chart below shows.
ADIL - Share of the company's book capitalization ADIL within the market segment - Narco farm
Adial Pharmaceuticals develops drugs for the treatment of addictions. Its scientific activities require a resource base: a laboratory for developing and testing targeted drugs and managing clinical trials. The chart shows the company's share of the physical R&D infrastructure in this complex segment.
Market segment balance sheet capitalization - Narco farm
Adial Pharmaceuticals is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Adial focuses on drug development, and its capital lies in its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Adial Pharmaceuticals' assets are not production lines, but capital allocated to the development of a genetically targeted drug for the treatment of alcohol addiction. The book value reflects the financial resources for clinical trials of this personalized therapy approach. The chart shows its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol addiction. Its market capitalization is an estimate of its chances of success in this vast and socially significant, yet challenging, area of drug development.
Market to book capitalization ratio in a market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol addiction. Its valuation on this chart reflects its success in clinical trials and the potential for its product to find a niche in the vast but complex addiction treatment market, where the need for new treatments is high.
Market to book capitalization ratio for the market as a whole
Adial Pharmaceuticals develops drugs to treat addictions. The company's value is determined by its patents and clinical trial results. This chart shows the premium investors are willing to pay to address pressing social and medical problems, even if commercial success is not yet guaranteed.
Debts of the company, segment and market as a whole
ADIL - Company debts ADIL
Adial, a biopharmaceutical company developing drugs for addiction treatment, is in the clinical stage and relies on external funding. This chart shows how the company raises funds to conduct the expensive clinical trials necessary to obtain regulatory approval for its targeted drug.
Market segment debts - Narco farm
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing a drug to treat alcohol use disorder. This chart shows how the company is funding its expensive clinical trials, aiming to offer a new approach to addiction treatment, a complex yet socially significant endeavor.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol use disorder in people with certain genetic markers. Clinical trials for addiction treatment are a long and complex process. This chart shows how the company is using debt to finance its high-risk, yet socially significant, research.
Market segment debt to market segment book capitalization - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders based on genetic testing. This is a personalized approach to medicine. This chart shows how the company is funding its clinical trials, comparing its debt structure to the overall biotech landscape.
Debt to book value of all companies in the market
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders. This is a socially significant yet complex area of pharmaceuticals. How dependent is the company on debt to finance its clinical trials? This graph of total debt in the economy allows us to assess the riskiness of its financial model.
P/E of the company, segment and market as a whole
P/E - ADIL
Adial Pharmaceuticals is a biopharmaceutical company developing a genetically targeted drug for the treatment of alcohol addiction. This chart shows how investors value its personalized treatment approach. The valuation is heavily dependent on clinical trial results and potential market size.
P/E of the market segment - Narco farm
Adial Pharmaceuticals is a biopharmaceutical company developing a personalized drug for the treatment of alcohol use disorder based on genetic testing. This chart illustrates the average valuation in the pharmaceutical sector, where investors evaluate the potential of precision medicine for treating addiction.
P/E of the market as a whole
Adial Pharmaceuticals is a biopharmaceutical company developing a genetically targeted drug for the treatment of alcohol use disorders. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether ADIL's valuation is based on faith in its unique approach to treating alcoholism or is moving in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ADIL
Adial Pharmaceuticals is developing a treatment for alcohol use disorders, targeting patients with specific genetic markers. This personalized approach is a key feature. This chart illustrates investors' confidence in the potential of targeted alcoholism therapy and the commercial prospects of Adial's product.
%20P%2FE%20ADIL&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ADIL&v=1772529197378 "Chart of the company's future (projected) P/E ADIL")
Future (projected) P/E of the market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol addiction in people with certain genetic markers. This is a personalized approach to treatment. The chart shows future profit expectations in the sector, helping to understand how much investors believe in the commercial potential of this targeted approach in psychiatry.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Narco-farm&v=1772529197440 "Future (projected) P/E graph of the market segment - Narco farm")
Future (projected) P/E of the market as a whole
Adial Pharmaceuticals is developing a drug to treat alcohol addiction in people with certain genetic markers. This is a personalized approach to therapy. This market sentiment chart shows how willing investors are to invest in innovative approaches to treating addiction, which is a huge social and medical problem.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772529197487 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ADIL
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing a drug to treat alcohol dependence in people with a specific genetic marker. Revenue depends on the success of trials and regulatory approval. This chart shows the financial trajectory of the company, which is focused on personalized medicine in a complex therapeutic area.
Profit of companies in the market segment - Narco farm
Adial Pharmaceuticals is developing a targeted drug to treat alcohol use disorder in patients with a specific genetic profile. This is an example of personalized medicine. This graph shows the overall profitability of the addiction treatment sector, where there is a huge unmet need for effective and safe therapies.
Overall market profit
Adial Pharmaceuticals develops medications to treat alcohol use disorders. The need for effective addiction treatment is a serious social issue and is not dependent on the state of the economy. The company's success is determined by the results of clinical trials, not by macroeconomic trends, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol use disorder in individuals with certain genetic markers. Future profits depend on the success of clinical trials and the adoption of personalized medicine in addiction treatment. This chart shows analysts' expectations for this innovative approach.
%20profit%20of%20the%20company%20ADIL&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ADIL&v=1772529197763 "Graph of future (projected) profit of the company ADIL")
Future (predicted) profit of companies in the market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders in people with a specific genetic profile. This personalized approach could be a breakthrough in alcoholism treatment. The company's success depends on clinical trials. This chart shows revenue projections for the pharmaceutical sector, providing context for Adial's valuation.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Narco-farm&v=1772529197839 "Graph of future (predicted) profits of companies in a market segment - Narco farm")
Future (predicted) profit of the market as a whole
Adial Pharmaceuticals is developing drugs to treat alcohol use disorders. Its future depends on the success of clinical trials and regulatory approval. This economic outlook affects the overall investment climate in the biotech sector, which is crucial for the funding of such companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772529197896 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders. It has no revenue at the clinical stage. This chart shows how investors assess the potential market for its targeted therapy. Its dynamics depend entirely on news about the progress of clinical trials.
P/S market segment - Narco farm
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company developing a genetically targeted drug for the treatment of alcohol use disorders. Their approach could offer a personalized solution for millions of people. This chart reflects the average revenue estimate for the sector, helping to assess the potential of this innovative approach.
P/S of the market as a whole
Adial Pharmaceuticals is developing a drug to treat alcohol addiction, targeting patients with specific genetic markers. This chart shows that the valuation of such biopharmaceutical companies is based on the potential market size for their targeted therapy, which can justify a high valuation even without revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ADIL
Adial Pharmaceuticals is developing a targeted drug for the treatment of alcohol use disorders. For such a company, future revenue estimates are crucial. They reflect investor expectations for the drug's success in clinical trials and its potential to carve out a niche in the large alcohol addiction treatment market by offering a personalized approach.
%20P%2FS%20ADIL&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ADIL&v=1772529198182 "The graph of the company's future (projected) P/S ADIL")
Future (projected) P/S of the market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders in people with certain genetic markers. This chart compares the company's estimated future sales with industry expectations. It shows how investors view the prospects of a personalized approach to alcoholism treatment and the results of clinical trials.
%20P%2FS%20market%20segment%20graph%20-%20Narco%20farm&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Narco-farm&v=1772529198219 "Future (projected) P/S market segment graph - Narco farm")
Future (projected) P/S of the market as a whole
Adial Pharmaceuticals is developing a genetically targeted drug for the treatment of alcohol use disorders. The company's success depends on the results of clinical trials and recognition of its personalized approach to addiction treatment. This graph of investor expectations reflects their view on the potential of personalized medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772529198260 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ADIL
This chart shows the revenue of Adial Pharmaceuticals, a biopharmaceutical company developing a drug to treat alcohol dependence in people with a specific genetic profile. Being in clinical trials, the company has no commercial sales revenue. Financial activity is driven by R&D expenses.
Sales of companies in the market segment - Narco farm
Adial Pharmaceuticals is developing a drug for the treatment of alcohol use disorders. Being in the clinical stage, the company has no sales revenue yet. Its future revenue will depend entirely on the success of its lead candidate, AD04, in obtaining regulatory approval and subsequently entering the market.
Overall market sales
Adial Pharmaceuticals develops medications for the treatment of alcohol use disorders. The company aims to address a serious social and medical problem. This general economic outlook does not affect the fundamental need for effective addiction treatments, which remains high regardless of economic cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ADIL
Adial Pharmaceuticals is a biopharmaceutical company developing a genetically targeted drug for the treatment of alcohol use disorders. Future revenue depends on the success of clinical trials and the commercialization of this personalized approach. This chart shows analyst forecasts for the potential market size for alcohol addiction treatment.
%20sales%20of%20the%20company%20ADIL&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ADIL&v=1772529198589 "Schedule of future (projected) sales of the company ADIL")
Future (projected) sales of companies in the market segment - Narco farm
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders based on genetic testing. This chart shows the forecast for the pharmaceutical market. Is demand for personalized approaches to addiction treatment growing? This reflects general trends in this socially significant field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Narco-farm&v=1772529198643 "Schedule of future (projected) sales of companies in the market segment - Narco farm")
Future (projected) sales of the market as a whole
Adial Pharmaceuticals develops medications to treat alcohol use disorders. Demand for such treatment is determined by public health and healthcare systems, not economic cycles. This timeline is of minimal significance, as the need for addiction treatment is a pressing medical and social issue.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772529198691 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol use disorders in patients with certain genetic markers. This chart shows the financial trajectory of the company, which is focused on personalized medicine. Profitability depends on the results of clinical trials and potential approval of the drug, which could change the approach to alcoholism treatment.
Market segment marginality - Narco farm
Adial Pharmaceuticals, Inc. is a biopharmaceutical company developing a drug for the treatment of alcohol use disorders. This chart reflects its financial position at the clinical stage, where profitability is entirely dependent on clinical trial results, FDA approval, and successful commercialization of its targeted approach to addiction treatment.
Market marginality as a whole
Adial Pharmaceuticals develops medications for the treatment of alcohol use disorders. The company operates at the intersection of medicine and addressing a serious social problem. This overall profitability chart reflects the state of the economy, which impacts healthcare funding and the system's readiness to implement new approaches to addiction treatment.
Employees in the company, segment and market as a whole
Number of employees in the company ADIL
Adial Pharmaceuticals is developing a drug to treat alcohol dependence in people with certain genetic markers. Its small team is managing the clinical trial process. This chart shows how the company is focusing its limited resources on achieving key trial results that will determine its future.
Share of the company's employees ADIL within the market segment - Narco farm
Adial Pharmaceuticals is developing a targeted drug for the treatment of alcohol use disorders. The company's activities are focused on clinical trials. This graph shows its market share in the pharmaceutical industry, which is an indicator of the scale of its clinical program and the stage of product development toward commercialization.
Number of employees in the market segment - Narco farm
Adial Pharmaceuticals is developing a genetically targeted drug for the treatment of alcohol use disorders. This chart shows employment in the addiction pharmaceuticals sector. Adial's personalized approach, based on a genetic marker, could revolutionize alcohol addiction treatment, targeting those who benefit from it.
Number of employees in the market as a whole
Adial Pharmaceuticals develops drugs to treat addiction disorders. This is a socially significant area, and the company's growth is determined not by economics but by success in clinical trials. This chart shows general trends, but Adial represents a sector where job creation is directly linked to addressing pressing public health issues.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ADIL (ADIL)
Adial Pharmaceuticals develops medications to treat alcohol use disorders. They are a biotech company with a clear focus. This chart shows the market value of their lead drug, AD04. It reflects the market value per employee, which essentially represents the success of their clinical trials.
%20of%20the%20company%20ADIL%20(ADIL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ADIL-ADIL&v=1772529199209 "Chart of market capitalization per employee (in thousands of dollars) of the company ADIL (ADIL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Narco farm
Adial Pharmaceuticals (ADIL) is developing a genetically targeted drug for the treatment of alcohol use disorders. For companies working with addiction, this metric reflects the potential of their approach. A high employee rating may indicate that their drug has the potential to help a specific group of patients, opening up a large commercial market.
%20by%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Narco-farm&v=1772529199280 "Market capitalization per employee (in thousands of dollars) by market segment - Narco farm")
Market capitalization per employee (in thousands of dollars) for the overall market
Adial Pharmaceuticals is developing a drug to treat alcohol addiction in people with a specific genetic profile. This is personalized medicine. The graph shows a high valuation per employee, as the market sees great potential in this targeted approach, which could prove significantly more effective than existing treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772529199321 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ADIL (ADIL)
Adial Pharmaceuticals is a clinical-stage biotech company developing a drug for the treatment of alcohol use disorders. This chart shows its R&D workload. The negative figure (loss per employee) reflects how much capital the company invests in each scientist and physician to conduct clinical trials.
%20Chart%20ADIL%20(ADIL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ADIL-ADIL&v=1772529199421 "Company Profit Per Employee (in thousands of dollars) Chart ADIL (ADIL)")
Profit per employee (in thousands of dollars) in the market segment - Narco farm
Adial Pharmaceuticals develops drugs to treat addiction-related disorders. In this socially significant pharmaceutical niche, the team's effectiveness is determined by the speed and success of clinical trials. The chart reflects the financial return per employee, which is an indicator of progress toward the commercialization of life-saving drugs.
%20in%20the%20market%20segment%20-%20Narco%20farm&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Narco-farm&v=1772529199521 "Chart of profit per employee (in thousands of dollars) in the market segment - Narco farm")
Profit per employee (in thousands of dollars) for the market as a whole
Adial Pharmaceuticals is a biotech company focused on treating addictions, particularly alcoholism, with a genetically targeted drug. It's an R&D company. This chart, showing average profitability, helps clarify the contrast with biotech, where a team of scientists burns through investors' capital in hopes of drug approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772529199622 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ADIL (ADIL)
Adial Pharmaceuticals develops drugs to treat addictions. At the clinical stage, revenue per employee is minimal. This graph is important for assessing potential: a successful drug for such a huge market could generate billions in sales, leading to explosive growth in this efficiency metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ADIL-ADIL&v=1772529199824 "Sales chart per company employee ADIL (ADIL)")
Sales per employee in the market segment - Narco farm
Adial Pharmaceuticals is a clinical-stage biotech developing a drug (AD04) for the treatment of alcohol use disorders. They have no commercial revenue. This chart, showing the average revenue in the sector, serves as a benchmark for ADIL's R&D staffing efficiency compared to other biotechs in this complex field.
Sales per employee for the market as a whole
Adial Pharmaceuticals is a biotech company developing a targeted drug for the treatment of alcohol use disorder. Their business is R&D. This graph reflects their clinical stage: the company is investing in research and trials to prove the effectiveness of their drug and does not yet have any sales revenue.
Short shares by company, segment and market as a whole
Shares shorted by company ADIL (ADIL)
Adial Pharmaceuticals (ADIL) is developing a drug to treat alcohol addiction, targeting individuals with specific genetic markers. This chart shows the volume of bearish bets. The shorts may be due to the company's previous clinical trial failures or skepticism that such a highly targeted drug will find a broad market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ADIL-ADIL&v=1772529200105 "Short Shares Chart for the Company ADIL (ADIL)")
Shares shorted by market segment - Narco farm
Adial Pharmaceuticals (ADIL) is a biotech company developing a genetically targeted drug (AD04) for the treatment of alcohol use disorders. This chart aggregates short positions across the biotech sector. It reflects investor skepticism about this complex area of research and the risks of clinical trials.
Shares shorted by the overall market
Adial (ADIL) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ADIL (ADIL)
Adial Pharmaceuticals (ADIL) is developing AD04, a drug for the treatment of alcohol use disorders based on genetic targeting. This is an important societal issue. This chart measures the rate of price change. It shows when the stock is "overheated" (above 70) pending trial data or "oversold" (below 30) following delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ADIL-ADIL&v=1772529200167 "RSI 14 indicator chart for the company's stock ADIL (ADIL)")
RSI 14 Market Segment - Narco farm
Adial Pharmaceuticals is a biopharmaceutical company developing a genetically targeted drug (AD04) for the treatment of alcohol use disorder (alcoholism). This chart shows the overall sentiment in the addiction pharma sector. It helps assess how investors view this niche and how Adial stacks up against it.
RSI 14 for the overall market
Adial Pharmaceuticals (ADIL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADIL (ADIL)
Adial Pharmaceuticals is a biopharmaceutical company developing AD04, a targeted therapy designed to treat alcohol use disorder (AUD) in patients with a specific genotype. This chart shows the speculative average price target from analysts, based on their confidence in the clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADIL-ADIL&v=1772529200301 "A chart showing analyst consensus forecasts for the expected stock price. ADIL (ADIL)")
The difference between the consensus estimate and the actual stock price ADIL (ADIL)
Adial is a biopharmaceutical company developing a drug (AD04) that targets a genetic predisposition to alcohol addiction. This chart measures the gap between the current price and the consensus target price. It shows the potential analysts see in this personalized approach to addiction treatment.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADIL-ADIL&v=1772529200341 "A chart showing the difference between the consensus forecast and the actual stock price. ADIL (ADIL)")
Analyst consensus forecast for stock prices by market segment - Narco farm
Adial (ADIL) is a biotech company developing a genetically targeted drug (AD04) for the treatment of alcohol addiction. This chart shows general expectations for the pharmaceutical sector. It reflects whether experts believe in a breakthrough in R&D in addiction treatment or consider the market too complex.
Analysts' consensus forecast for the overall market share price
Adial Pharmaceuticals is a biotech company developing a drug (AD04) for the treatment of alcohol use disorders, targeting patients with specific genes. This chart reflects the overall market "risk appetite." For Adial, a clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ADIL
Adial Pharmaceuticals is a biotech R&D company with one bet: AD04. It's a genetically targeted drug designed to treat alcohol dependence (AUD) in people with a specific genotype. This graph is a pure indicator of their R&D. Its progress is all or nothing, depending entirely on their (very risky) clinical trial data and their dialogue with the FDA.
AKIMA Market Segment Index - Narco farm
Adial Pharmaceuticals (ADIL) is developing a personalized medication (AD04) for the treatment of alcohol use disorder (AUD). Their approach is unique: the drug is designed only for patients with a specific genetic marker, increasing the chances of success. This graph shows the average index for the segment, helping to assess how this genetic strategy compares to the average.
The AKIM Index for the overall market
Adial Pharmaceuticals is a biopharmaceutical company developing genetically targeted drugs for the treatment of addictions (alcoholism). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this precision medicine story in psychiatry compares to overall economic trends.
